Orchestra BioMed Holdings, Inc.
NASDAQ:OBIOBiotechnology
+$0.05 today
- Market cap
- $587.14M
- Beta
- 0.50
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.42
Volume 1.20M
Average 0.22M
OBIO Net Income
Bottom-line profit after all expenses, interest, and taxes.
Orchestra BioMed Holdings, Inc.NASDAQ: OBIO
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income remains negative
Q1 FY2026 net income was -$20.69M, compared with -$18.76M a year earlier. Trailing-twelve-month net income was -$54.64M.
Context
- Net income amounted to 157.4% of revenue in FY2025, down 2155.9 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$65.29M (-23.9%) for the fiscal year ending Dec 2026, a slowdown from the +13.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$20.69M-431.3% QoQ
- Last fiscal yearDec 2025
- -$52.7M+13.6% YoY
- LTMMar 2026
- -$54.64M+17.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -10.3% | -130725.5% | -130715.1 pp |
| 1 year | +13.6% | -23.9% | -37.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- (52.7M) USD
- Year-over-year change
- +13.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (52.7M) | +13.6% |
| FY2024 | 2024-12-31 | (61.02M) | -24.2% |
| FY2023 | 2023-12-31 | (49.12M) | -46.2% |
| FY2022 | 2022-12-31 | (33.61M) | -46.0% |
| FY2021 | 2021-12-31 | (23.01M) | — |
Net Income vs competitors
How OBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +17.6% is the 5th highest of 11, against a peer median of +12.0%.
- Net income amounts to 167.0% of revenue for OBIO, versus a peer median of 889.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | -$42.49M USD | -62.1% | — | — |
| LTM Mar 2026 | -$54.64M USD | +17.6% | — | 167.0% | |
| LTM Mar 2026 | -$61.98M USD | +35.7% | — | 89.6% | |
| LTM Mar 2026 | -$63.31M USD | -39.4% | — | — | |
| LTM Mar 2026 | -$77.6M USD | +45.6% | — | 138.9% | |
| LTM Mar 2026 | -$77.8M USD | +39.1% | — | 465.3% | |
| LTM Mar 2026 | -$81.74M USD | +14.2% | — | 589.8% | |
| LTM Mar 2026 | -$83.01M USD | +21.5% | — | 36891.1% | |
| LTM Mar 2026 | -$84.74M USD | -216.1% | — | 143627.1% | |
| LTM Mar 2026 | -$133.22M USD | +9.9% | — | 1189.1% | |
| FY2025 | -€340.16M EUR | -84.7% | — | 7587.8% | |
| Peer median (excluding OBIO) | — | +12.0% | — | 889.5% | |
Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | (782K) | 3.53M | 2.76M | 2.64M | 33.48M |
| Cost of Revenue | 199K | 322K | 186K | 204K | 190K |
| Gross Profit | (981K) | 3.21M | 2.57M | 2.43M | 33.29M |
| Gross Margin | 125.4% | 90.9% | 93.3% | 92.3% | 99.4% |
| Research & Development | 12.89M | 21.95M | 33.82M | 42.8M | 58.19M |
| Selling, General & Admin | 7.93M | 13.92M | 20.26M | 23.93M | 26.91M |
| Operating Expenses | 20.82M | 35.87M | 54.08M | 66.74M | 85.1M |
| Depreciation & Amortization | 181K | 222K | 287K | 308K | 327K |
| EBITDA | (21.91M) | (33.39M) | (48.83M) | (60.72M) | (51.23M) |
| EBITDA Margin | 2801.3% | -945.0% | -1769.3% | -2301.6% | -153.0% |
| Operating Income | (21.8M) | (32.66M) | (51.51M) | (64.3M) | (51.81M) |
| Operating Margin | 2787.6% | -924.3% | -1866.2% | -2437.5% | -154.7% |
| Interest Income | 0 | 50K | 3.85M | 3.36M | 0 |
| Interest Expense | 927K | 0 | 0 | 0 | 1.15M |
| Other Income / Expenses | (1.22M) | (951K) | 2.39M | 3.28M | (894K) |
| Income Before Tax | (23.01M) | (33.61M) | (49.12M) | (61.02M) | (52.7M) |
| Pre-Tax Margin | 2943.0% | -951.3% | -1779.7% | -2313.3% | -157.4% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (23.01M) | (33.61M) | (49.12M) | (61.02M) | (52.7M) |
| Net Margin | 2943.0% | -951.3% | -1779.7% | -2313.3% | -157.4% |
| EPS (Basic) | (0.02) | (1.32) | (1.48) | (1.66) | (1.38) |
| EPS (Diluted) | (0.02) | (1.32) | (1.48) | (1.66) | (1.38) |
| Weighted Avg Shares | 20.45M | 25.47M | 33.23M | 36.82M | 38.39M |
| Weighted Avg Shares (Diluted) | 20.45M | 25.47M | 33.23M | 36.82M | 38.39M |
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
Intrinsic Alpha fair value
Locked
Current Price
$7.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.